Stock Research: Pacira BioSciences

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Pacira BioSciences

NasdaqGS:PCRX US6951271005
79
  • Value
    84
  • Growth
    85
  • Safety
    Safety
    82
  • Combined
    100
  • Sentiment
    12
  • 360° View
    360° View
    79
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Pacira BioSciences is a pharmaceutical company specializing in non-opioid treatments for pain management. The company operates in the pharmaceutical industry, with key products including EXPAREL, ZILRETTA, and iovera. Pacira BioSciences operates in the US. In the last fiscal year, the company had 790 employees, a market cap of $1,060 million, profits of $531 million, and revenue of $701 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 79 (better than 79% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Pacira BioSciences are very positive. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators above average for Pacira BioSciences. The consolidated Value Rank has an attractive rank of 82, which means that the share price of Pacira BioSciences is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 82% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 85, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. The company is also safely financed with a Safety Rank of 84. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of only 12. Professional investors are more confident in 88% other stocks. ...read more

more
Index
NASDAQ
D.J. US Pharmaceutical
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
82 74 49 29
Growth
85 67 79 65
Safety
Safety
84 79 58 61
Sentiment
12 44 75 30
360° View
360° View
79 91 91 40
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
13 11 64 43
Opinions Change
50 82 50 11
Pro Holdings
n/a 82 63 61
Market Pulse
13 19 63 70
Sentiment
12 44 75 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
82 74 49 29
Growth
85 67 79 65
Safety Safety
84 79 58 61
Combined
100 100 81 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
80 90 75 63
Price vs. Earnings (P/E)
68 57 46 30
Price vs. Book (P/B)
68 61 50 38
Dividend Yield
1 1 1 1
Value
82 74 49 29
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
56 54 64 69
Profit Growth
25 43 60 71
Capital Growth
87 94 78 31
Stock Returns
91 39 47 55
Growth
85 67 79 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
42 49 36 42
Refinancing
75 67 59 51
Liquidity
73 66 64 65
Safety Safety
84 79 58 61

Similar Stocks

Discover high‑ranked alternatives to Pacira BioSciences and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Intuit

NasdaqGS:INTU
Country: USA
Industry: Application Software
Size: X-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.